Page
%P
-
Article
Open AccessThe PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor e...